Efficacy and Safety of Rivaroxaban in Patients with Peripheral Artery Disease: A GRADE-assessed Systematic Review and Meta-Analysis
Annals of Vascular Surgery · 2026
DOI: 10.1016/j.avsg.2026.06.047 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Vascular Surgery, 2026. Verfasst von Muhammad Shahzaib und 11 weiteren Autor:innen. Beteiligte Einrichtung: King Edward Medical University, Lahore, Pakistan. Hauptthemen laut MEDLINE: Rivaroxaban, Peripheral Arterial Disease, Factor Xa Inhibitors. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Peripheral artery disease (PAD) is a common atherosclerotic disorder characterized by progressive arterial narrowing in the limbs. This study aims to determine the efficacy and safety of rivaroxaban, focusing on major cardiovascular events, limb outcomes, and bleeding risks. METHODS: PubMed, Cochrane, and EMBASE were searched for randomized controlled trials (RCTs) and nonrandomized comparative studies that compared rivaroxaban, either alone or in combination with aspirin, to placebo or standard care such as antiplatelet therapy. Risk ratios and hazard ratios with 95% confidence intervals were pooled using R v4.5.1 with an appropriate random-effects model applied. Subgroup analyses were performed according to rivaroxaban plus aspirin versus rivaroxaban alone. RESULTS: A total of 39,991 participants across 6 studies were included. Compared with control, use of rivaroxaban was linked to a significant reduction in composite efficacy outcomes (relative risk [RR] = 0.84, 95% confidence interval [CI] 0.78-0.91, P < 0.001), risk of acute limb ischemia (RR = 0.65, 95% CI 0.55-0.78, P < 0.001), and thromboembolism (RR = 0.60, 95% CI 0.38-0.97, P = 0.037). Although rivaroxaban plus aspirin failed to show a significant reduction in the risk of amputation, rivaroxaban alone reported a significant risk reduction (RR = 0.50, 95% CI 0.30-0.85, P = 0.003). However, its use was associated with a significantly higher risk of major bleeding (hazard ratio [HR] = 1.54, 95% CI 1.38-1.72, P < 0.001) and International Society on Thrombosis and Hemostasis-defined bleeding (RR = 1.45, 95% CI 1.19-1.76, P < 0.001). No significant differences were observed for stroke, myocardial infarction, major adverse limb events, fatal bleeding, mortality, or cardiovascular mortality. CONCLUSION: Rivaroxaban-based therapy reduced the trial-defined composite efficacy outcome, acute limb ischemia, and thromboembolism in patients with PAD, but increased the risk of major bleeding. These findings support individualized use of rivaroxaban-based therapy in carefully selected patients, balancing ischemic and limb-protective benefits against bleeding risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- King Edward Medical University, Lahore, Pakistan.
- King Edward Medical University, Lahore, Pakistan. Electronic address: mroshaan2002@gmail.com.
- Jinnah Sindh Medical University, Karachi, Pakistan.
- United Health Services Wilson Medical Center, Johnson City, NY.
- Al-Kindy College of Medicine, University of Baghdad, Baghdad, Iraq.
- Khawaja Muhammad Safdar Medical College, Sialkot, Pakistan.
Zitieren
APA
Shahzaib, M., Roshaan, M., Buhadur Ali, M. K., Hussain, S. I., Khan, N. A., Haiy, A. U., Hamzah, K. A., Shahryar, M., Shahzad, E., Afzal, N., Liaqat, F., & Hasan, A. H. (2026). Efficacy and Safety of Rivaroxaban in Patients with Peripheral Artery Disease: A GRADE-assessed Systematic Review and Meta-Analysis. Annals of Vascular Surgery. https://doi.org/10.1016/j.avsg.2026.06.047
Vancouver
Shahzaib M, Roshaan M, Buhadur Ali MK, Hussain SI, Khan NA, Haiy AU, et al. Efficacy and Safety of Rivaroxaban in Patients with Peripheral Artery Disease: A GRADE-assessed Systematic Review and Meta-Analysis. Annals of Vascular Surgery. 2026. doi:10.1016/j.avsg.2026.06.047
BibTeX
@article{Shahzaib2026,
author = {Shahzaib, Muhammad and Roshaan, Muhammad and Buhadur Ali, Muhammad Khan and Hussain, Syed Ibad and Khan, Noraiz Abbas and Haiy, Ata Ul and Hamzah, Khadeeja Ali and Shahryar, Muhammad and Shahzad, Eman and Afzal, Nimra and Liaqat, Fizza and Hasan, Abdul Haseeb},
title = {Efficacy and Safety of Rivaroxaban in Patients with Peripheral Artery Disease: A GRADE-assessed Systematic Review and Meta-Analysis},
journal = {Annals of Vascular Surgery},
year = {2026},
doi = {10.1016/j.avsg.2026.06.047}
}
EUVIMED